Deciphera Pharmaceuticals (NASDAQ:DCPH) had its price objective lowered by Canaccord Genuity from $55.00 to $50.00 in a research note published on Friday morning. The brokerage currently has a buy rating on the stock.
Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Deciphera Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, February 12th. BidaskClub lowered Deciphera Pharmaceuticals from a hold rating to a sell rating in a report on Saturday, December 22nd. Cantor Fitzgerald reissued a buy rating and issued a $53.00 price objective on shares of Deciphera Pharmaceuticals in a report on Thursday, December 20th. B. Riley lowered Deciphera Pharmaceuticals from a buy rating to a neutral rating in a report on Tuesday, January 1st. Finally, Leerink Swann decreased their price objective on Deciphera Pharmaceuticals from $28.00 to $20.00 and set an underperform rating for the company in a report on Friday, November 16th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $42.11.
Shares of DCPH stock opened at $25.29 on Friday. Deciphera Pharmaceuticals has a 12-month low of $18.55 and a 12-month high of $45.61. The company has a market capitalization of $952.45 million, a P/E ratio of -8.46 and a beta of 3.27. The company has a debt-to-equity ratio of 0.06, a current ratio of 18.46 and a quick ratio of 18.46.
In other Deciphera Pharmaceuticals news, insider Michael Douglas Taylor sold 1,700 shares of the company’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $28.01, for a total value of $47,617.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Thomas Patrick Kelly sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $30.00, for a total value of $45,000.00. The disclosure for this sale can be found here. Insiders sold 198,426 shares of company stock valued at $5,247,846 over the last 90 days. 20.61% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can acquired a new stake in Deciphera Pharmaceuticals in the fourth quarter worth approximately $50,000. Legal & General Group Plc lifted its position in Deciphera Pharmaceuticals by 55.4% in the third quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after purchasing an additional 587 shares during the period. Bank of America Corp DE lifted its position in Deciphera Pharmaceuticals by 316.1% in the second quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after purchasing an additional 1,982 shares during the period. MetLife Investment Advisors LLC acquired a new stake in Deciphera Pharmaceuticals in the third quarter worth approximately $235,000. Finally, Rhumbline Advisers lifted its position in Deciphera Pharmaceuticals by 53.6% in the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after purchasing an additional 4,000 shares during the period. Hedge funds and other institutional investors own 57.28% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Recommended Story: Investing strategies using the yield curve
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.